Reji Pappy, MD
Cardiovascular Disease · Oklahoma City, OKNPI 1154462802
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,264 of the $24,907 with a category attached, or 61.3%. 28 manufacturers reported payments, led by Abbott at 40.5% of the total. Reporting peaked in 2019 at $10,642 and has fallen 89.2% since, to $1,147 in 2025. Among cardiovascular disease clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $82.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Medtronic$8K
- Boston Scientific$2K
- Edwards Lifesciences$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$839
- Atricure, Inc.$625
- plus $2K from 22 others
What the payments were for
- Travel & lodging$9,63539%
- Food & beverage$15,26461%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 128 | $10,093 |
| Medtronic(2 entities) | 41 | $7,987 |
| Boston Scientific | 31 | $1,756 |
| Edwards Lifesciences | 16 | $1,380 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $839 |
| Atricure, Inc. | 12 | $625 |
| Johnson & Johnson | 12 | $531 |
| Penumbra, Inc. | 3 | $363 |
| Shockwave Medical, Inc | 4 | $265 |
| Philips North America LLC | 8 | $180 |
| Cvrx, Inc. | 1 | $176 |
| Abiomed | 2 | $169 |
| Alnylam Pharmaceuticals Inc. | 2 | $142 |
| Impulse Dynamics (USA) Inc. | 1 | $78 |
| Heartflow, Inc. | 1 | $54 |
| Angiodynamics, Inc. | 1 | $42 |
| Surmodics, Inc. | 3 | $31 |
| Biosense Webster, Inc. | 1 | $24 |
| Endologix LLC | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Novartis | 1 | $21 |
| Amgen | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Pfizer | 1 | $14 |
| GE HealthCare | 1 | $13 |
| Inari Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$6,118
- MitraClip$1,809
- Xience V coronary stent system$1,402
- EnSite Precision Cardiac Mapping System$1,153
- Watchman$756
- COREVALVE EVOLUT R$521
- Mitra Clip system$414
- Xience Sierra Coronary Stent System$407
- XARELTO$380
- Indigo System$363
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$353
- Connect HF$314
- GALLANT$293
- Xience Sierra Coronary Stent$256
- WATCHMAN Access System$221
- Barostim Neo System$176
- Reveal LINQ$153
- PASCAL$151
- COROFLOW$151
- CARDIOMEMS$150
How this compares
$24,907 in reported general payments places this provider in the 90th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 332 | $372,300 |
| XareltoRivaroxaban | 82 | $101,336 |
| BrilintaTicagrelor | 103 | $86,133 |
| EntrestoSacubitril/Valsartan | 59 | $81,010 |
| Repatha SureclickEvolocumab | 34 | $35,542 |
| FarxigaDapagliflozin Propanediol | 16 | $24,013 |
| Praluent PenAlirocumab | 25 | $17,775 |
| ClopidogrelClopidogrel Bisulfate | 493 | $6,364 |
| Metoprolol Succinate | 254 | $4,256 |
| Atorvastatin Calcium | 348 | $4,254 |
| Carvedilol | 365 | $3,464 |
| Ranolazine ErRanolazine | 26 | $2,170 |
| Losartan Potassium | 125 | $1,792 |
| Amlodipine Besylate | 179 | $1,720 |
| Lisinopril | 207 | $1,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $372,300332 claims |
| AstraZenecaBrilinta, Farxiga | $16 | $110,146119 claims |
| Johnson & JohnsonXarelto | $531 | $101,33682 claims |
| NovartisEntresto | $21 | $81,01059 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Oklahoma City
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Udho ThadaniOklahoma City$41K
- Robert SullivanOklahoma City$36K
- Sandeep ChopraOklahoma City$15K
- Jered CookOklahoma City$14K
- William CollazoOklahoma City$11K
- Vinodh JeevananthamOklahoma City$11K
- Niraj PrasadOklahoma City$10K
- Jeffrey AsburyOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.